Heabo Medicine-B(02142) and Solstice Oncology enter into an exclusive licensing agreement and equity cooperation agreement regarding HBM4003

iFintech News APP reports that Hutchison China MediTech Limited (02142) announced that the company has entered into an exclusive licensing agreement and equity cooperation agreement with Solstice Oncology (a clinical-stage biotechnology company founded by multiple large venture capital firms). Under these agreements, the company has agreed to grant Solstice Oncology exclusive rights to develop and commercialize its clinical-stage portfolio asset HBM4003 outside Greater China.

According to the terms of the agreements, the company is eligible to receive upfront consideration exceeding $105 million, including a $50 million initial payment, a $5 million near-term payment, and issuance and allocation of over $50 million in equity to the company by Solstice Oncology. Additionally, the company may qualify for up to approximately $1.1 billion in additional milestone payments for development, regulatory, and commercial achievements, depending on the achievement of certain future events, as well as tiered royalties based on net sales of HBM4003 outside Greater China.

The company will leverage this opportunity to strengthen its global collaboration network through innovative partnership models, maximizing the scientific and commercial value of its technology platform. Establishing these agreements can accelerate the global development and commercialization of HBM4003 outside Greater China by co-building a global biotechnology company focused on HBM4003 with experienced investment institutions. This partnership model not only enables long-term value creation but also allows the company to deeply participate in and promote the global development of this asset.